This is one of a series of news items from abstracts of studies presented at the Annual Meeting of the American Society for Reproductive Medicine as complied by Dr. David Meldrum, Scientific Director of Reproductive Partners. We appreciate the enormous amount of work it takes to compile and comment on these abstracts.
AMH, anti-mullerian hormone fertility testing may have an increasing role based on two poster presentations at the Annual Meeting.
In one study, the success rate of IVF was reduced by about one third in women with an AMH less than1 ng/ml but even in women with levels less than 0.1 ng/ml, 5 pregnancies were observed. Low or undetectable AMH may prompt the use of additional measures to try to improve response, but it should not in itself exclude a patient from trying IVF.
In a second study, over 15,000 serum levels for AMH were examined relative to age. AMH was highly correlated with age. In the future nomograms will be available for patients to assess their ovarian age relative to their chronological age to make informed decisions regarding egg freezing for fertility preservation. This reason for doing IVF is expected to grow over the years and AMH determinations can be expected to be a driving force.
